

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or any state securities law of the United States. The securities may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States. The Offer Shares are being offered and sold solely (1) to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act; and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the prospectus dated May 5, 2026 (the “**Prospectus**”) issued by IMPACT Therapeutics, Inc (南京英派藥業股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus.

Unless otherwise defined in this announcement, capitalized terms used herein shall have the same meanings as those defined in the Prospectus.

In connection with the Global Offering, Goldman Sachs (Asia) L.L.C., as the stabilization manager (the “**Stabilization Manager**”), or any person acting for it and on behalf of the Underwriters, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilization Manager (or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilization Manager (or any person acting for it) and in what the Stabilization Manager reasonably regards as the best interest of the Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days of the last day for lodging applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date, and is expected to expire on Sunday, June 7, 2026, the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, demand for the Shares, and therefore the price of the Shares, could fall.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Wednesday, May 13, 2026).



**IMPACT Therapeutics, Inc**  
**南京英派藥業股份有限公司**

*(A joint stock company established in the People's Republic of China with limited liability)*

**GLOBAL OFFERING**

**Number of Offer Shares under the Global Offering** : 41,977,000 H Shares (subject to the Over-allotment Option)  
**Number of Hong Kong Offer Shares** : 4,197,800 H Shares  
**Number of International Offer Shares** : 37,779,200 H Shares (subject to the Over-allotment Option)  
**Final Offer Price** : HK\$20.10 per H Share, plus brokerage of 1.0%, AFRC transaction levy of 0.00015%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.00565%  
**Nominal value** : RMB1.00 per H Share  
**Stock code** : 7630

*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,  
Joint Bookrunners and Joint Lead Managers*

**Goldman  
Sachs**

 **CICC 中金公司**

*Joint Global Coordinator,  
Joint Bookrunner and Joint Lead Manager*

 **招銀国际**  
CMB INTERNATIONAL

*Joint Bookrunner and Joint Lead Manager*

 **老虎證券**  
TIGER BROKERS

# IMPACT Therapeutics, Inc 南京英派藥業股份有限公司

## ANNOUNCEMENT OF FINAL OFFER PRICE AND ALLOTMENT RESULTS

Warning: In view of high concentration of shareholding in a small number of H Shareholders, H Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated May 5, 2026 (the “**Prospectus**”) issued by IMPACT Therapeutics, Inc (南京英派藥業股份有限公司) (the “**Company**”).*

### SUMMARY

Company information	
Stock code	7630
Stock short name	IMPACT THERAP-B
Dealings commencement date	May 13, 2026*

\* see note at the end of the announcement

Price Information	
Final Offer Price	HK\$20.10
Offer Price Range	HK\$19.75 – HK\$21.75

Offer Shares and Share Capital	
Number of Offer Shares (before exercise of the Over-allotment Option)	41,977,000 H Shares
Final Number of Offer Shares in Hong Kong Public Offering	4,197,800 H Shares
Final Number of Offer Shares in International Offering (before exercise of the Over-allotment Option)	37,779,200 H Shares
Number of issued Shares upon Listing (before exercise of the Over-allotment Option)	276,165,130 Shares

Over-allocation	
Number of Offer Shares over-allocated	6,296,400

*Such over-allocation may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or through deferred delivery or a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange’s website.*

Proceeds	
<b>Gross proceeds<sup>(Note)</sup></b>	HK\$843.7 million
<b>Less: Estimated listing expenses payable based on Offer Price</b>	HK\$84.2 million
<b>Net proceeds</b>	HK\$759.5 million

*Note: Gross proceeds refers to the amount to which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” of the Prospectus. The Company will adjust the allocation of the net proceeds from the exercise of the Over-allotment Option (if any) for the purposes as set out in the section headed “Future Plans and Use of Proceeds” of the Prospectus on a pro rata basis.*

## ALLOTMENT RESULTS DETAILS

### HONG KONG PUBLIC OFFERING

<b>No. of valid applications</b>	221,788
<b>No. of successful applications</b>	18,774
<b>Subscription level</b>	2,282.4 times
<b>Claw-back triggered</b>	N/A
<b>No. of Offer Shares initially available under the Hong Kong Public Offering</b>	4,197,800 H Shares
<b>No. of Offer Shares reallocated from the International Offering (claw-back)</b>	N/A
<b>Final no. of Offer Shares under the Hong Kong Public Offering</b>	4,197,800 H Shares
<b>% of Offer Shares under the Hong Kong Public Offering to the Global Offering</b>	10.00%

*Note: For details of the final allocation of the H Shares to the Hong Kong Public Offering, investors can refer to [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) to perform a search by identification number or [www.eipo.com.hk/eIPOAllotment](http://www.eipo.com.hk/eIPOAllotment) for the full list of allottees.*

### INTERNATIONAL OFFERING

<b>No. of places</b>	137
<b>Subscription level</b>	24.58 times
<b>No. of Offer Shares initially available under the International Offering</b>	37,779,200 H Shares
<b>No. of Offer Shares reallocated to the Hong Kong Public Offering (claw-back)</b>	N/A
<b>Final no. of Offer Shares under the International Offering</b>	37,779,200 H Shares
<b>% of Offer Shares under the International Offering to the Global Offering</b>	90%

The Directors confirm that, to the best of their knowledge, information and belief, save for consents under paragraphs 1C(1) and 1C(2) of Appendix F1 to the Listing Rules (the “**Placing Guidelines**”) and waivers from strict compliance with the requirements under Rules 9.09(b)(if applicable) and 10.04 of the Listing Rules pursuant to Chapters 2.3 and 4.15 of the Guide for New Listing Applicants (“**Listing Guide**”) granted by the Stock Exchange to permit the Company to, among other things, place certain H Shares in the International Offering to certain existing Shareholders and/or their close associates and certain connected clients, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

### Cornerstone Investors

<i>Investor</i> <sup>Note 1</sup>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Existing shareholders or their close associates</i> <sup>Note 2</sup>
Nanjing Biotech and Pharmaceutical Valley Construction and Development Co., Ltd. (“BPV”) and Huatai Capital Investment Limited (“HTCI”) (in connection with Huatai Back-to-back TRS and the Huatai Client TRS)	4,775,600	11.38%	1.73%	No
Huang River Investment Limited (“Huang River”) <sup>Note 3</sup>	3,117,800	7.43%	1.13%	Yes
Prosper High Holding Limited (“Prosper High”) <sup>Note 3</sup>	776,000	1.85%	0.28%	Yes
LAV Star Limited (“LAV Star”) <sup>Note 4</sup>	974,200	2.32%	0.35%	Yes
LAV Star Opportunities Limited (“LAV Opportunities”) <sup>Note 4</sup>	974,200	2.32%	0.35%	Yes
Global Superior Choice Fund 1 SP (“GSC Fund 1”) <sup>Note 5</sup>	565,000	1.35%	0.20%	No
Vision Fund 1 SP (“Vision Fund 1”) <sup>Note 5</sup>	993,800	2.37%	0.36%	No

<i>Investor</i> <sup>Note 1</sup>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Existing shareholders or their close associates</i> <sup>Note 2</sup>
Horizon Fund 1 SP (“ <b>Horizon Fund 1</b> ”) <sup>Note 5</sup>	194,800	0.46%	0.07%	No
Horizon Next SP (“ <b>Horizon Next Fund</b> ”) <sup>Note 5</sup>	194,800	0.46%	0.07%	No
First Quarter Moon OFC – Phecda Fund	974,200	2.32%	0.35%	No
Worldwide Healthcare Partners LLC (“ <b>WWHCP</b> ”) <sup>Note 6</sup>	389,600	0.93%	0.14%	Yes
<b>Total</b>	<b>13,930,000</b>	<b>33.19%</b>	<b>5.03%</b>	

*Notes:*

- (1) For further details of the Cornerstone Investors, please refer to the section headed “Cornerstone Investors” in the Prospectus.
- (2) Among the Cornerstone Investors, WWHCP is an existing Shareholder, each of LAV Star, LAV Opportunities is a close associate of an existing Shareholder and a core connected person of the Company, and each of Huang River and Prosper High is a close associate of an existing Shareholder. The Stock Exchange has granted consents under paragraph 1C (2) of Appendix F1 of Placing Guidelines and Chapter 4.15 of the Listing Guide and a waiver from strict compliance from the requirements under Rule 9.09(b) and Rule 10.04 of the Listing Rules to permit each of WWHCP, LAV Star, LAV Opportunities, Huang River and Prosper High to participate in the International Offering as a cornerstone investor. Please refer to the section headed “Waivers and Exemptions – Consent and Waiver in respect of Allocation of H Shares to Certain Existing Shareholders and/or Their Close Associates” of the Prospectus for details.
- (3) Tencent Holdings Limited (騰訊控股有限公司), through Guangxi Tencent Venture Investment Co., Ltd. (廣西騰訊創業投資有限公司), owns approximately 6.66% of the total number of issued Shares of the Company before the Global Offering. Such shareholding is expected to be approximately 7.06% immediately following the completion of the Global Offering (and before any exercise of the Over-allotment Option), after taking into account the Shares to be subscribed by Huang River and Prosper High under the Cornerstone Investment.
- (4) As disclosed in the Prospectus, each of LAV Innovation Hong Kong Co., Limited, LAV Enterprise Hong Kong Limited, LAV Impetus Limited, and LAV Integra Limited (together, “**LAV USD**”) owns approximately 15.62% of the total number of issued Shares of the Company before the Global Offering. Such shareholding is expected to be approximately 13.95% immediately following the completion of the Global Offering (and before any exercise of the Over-allotment Option), after taking into account the Shares to be subscribed by LAV Star and LAV Opportunities under the Cornerstone Investment.
- (5) As disclosed in the Prospectus, GSC Fund 1, Vision Fund 1, Horizon Fund 1, and Horizon Next Fund are all sub-funds of Foresight Global Superior Choice SPC. Immediately following the completion of the Global Offering (and before any exercise of the Over-allotment Option), Foresight owns approximately 0.71% of the total number of issued Shares of the Company.
- (6) WWHCP owns approximately 0.14% of the total number of issued Shares of the Company before the Global Offering. Such shareholding is expected to increase to approximately 0.26% immediately following the completion of the Global Offering (and before any exercise of the Over-allotment Option), after taking into account the Shares to be subscribed by it under the Cornerstone Investment. Exome Asset Management LLC, through WWHCP and Emerging Markets Healthcare Partners LLC, in aggregate owns approximately 0.39% of the total number of issued Shares of the Company before the Global Offering, and approximately 0.47% immediately following the completion of the Global Offering (and before any exercise of the Over-allotment Option).



### *Allottees with Waivers/Consents Obtained*

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Relationship</i>
<i>Allottees with consent under paragraph 1C(2) of the Placing Guidelines and waiver from strict compliance with the requirements under Rule 9.09(b) (where applicable) and Rule 10.04 of the Listing Rules pursuant to Chapters 2.3 and 4.15 of the Listing Guide in relation to subscription for Offer Shares by existing Shareholder and/or their close associates<sup>Note 1</sup></i>				
WWHCP	389,600	0.93%	0.14%	An Existing Shareholder
LAV Star	974,200	2.32%	0.35%	A close associate of an existing Shareholder
LAV Opportunities	974,200	2.32%	0.35%	A close associate of an existing Shareholder
Huang River	3,117,800	7.43%	1.13%	A close associate of an existing Shareholder
Prosper High	776,000	1.85%	0.28%	A close associate of an existing Shareholder
CPIC Investment Management HK Limited (“ <b>CPIC IMHK</b> ”) <sup>Note 2</sup>	272,800	0.65%	0.10%	A close associate of an existing Shareholder
PACIFIC ASSET MANAGEMENT CO., LTD. (“ <b>Pacific Asset</b> ”) <sup>Note 2</sup>	1,091,200	2.60%	0.40%	A close associate of an existing Shareholder

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares (assuming the Over-allotment Option is not exercised)</i>	<i>% of total issued share capital after the Global Offering (assuming the Over-allotment Option is not exercised)</i>	<i>Relationship</i>
Wealth Shine Asia Pacific Limited (“ <b>Wealth Shine</b> ”) <i>Note 3</i>	311,800	0.74%	0.11%	A close associate of an existing Shareholder
STAR FOCUS GROUP LIMITED (“ <b>Star Focus</b> ”) <i>Note 4</i>	30,600	0.07%	0.01%	A close associate of an existing Shareholder
<b>Allottees with consent under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Listing Guide in relation to allocations to connected clients</b> <i>Note 5</i>				
CICC Financial Trading Limited (“ <b>CICC FT</b> ”)	5,800	0.0138%	0.0021%	A connected client
China Asset Management (Hong Kong) Limited (“ <b>China AMC</b> ”)	4,200	0.0100%	0.0015%	A connected client

*Notes:*

1. The Stock Exchange has granted a consent under paragraph 1C(2) of the Placing Guidelines and a waiver from strict compliance with the requirements under Rule 9.09(b) (where applicable) and 10.04 of the Listing Rules pursuant to Chapters 2.3 and 4.15 of the Listing Guide to permit Offer Shares be placed the above placees who are existing Shareholders and/or their close associates. Please refer to the section headed “Others/Additional Information – Allocation of H Shares to Certain Existing Shareholders and/or Their Close Associates” in this announcement.
2. Shanghai Kangjun Business Management Consulting Partnership (Limited Partnership) (上海康鑒企業管理諮詢合夥企業(有限合夥)) (“**Shanghai Kangjun**”) owns approximately 2.58% of the total number of issued Shares of the Company before the Global Offering. Such shareholding is expected to be approximately 2.68% immediately following the completion of the Global Offering (and before any exercise of the Over-allotment Option), after taking into account the Shares to be subscribed by CPIC IMHK and Pacific Asset under the International Offering.
3. Gongqingcheng Ruiji Fund III Investment Partnership (Limited Partnership) (共青城瑞吉三期投資合夥企業(有限合夥)) (“**Ruiji Fund III**”) owns approximately 1.01% of the total number of issued Shares of the Company before the Global Offering. Such shareholding is expected to be approximately 0.97% immediately following the completion of the Global Offering (and before any exercise of the Over-allotment Option), after taking into account the Shares to be subscribed by Wealth Shine under the International Offering.



4. *Eagle Mind Investments Limited (“Eagle Mind”) owns approximately 0.98% of the total number of issued Shares of the Company before the Global Offering. Such shareholding is expected to be approximately 0.84% immediately following the completion of the Global Offering (and before any exercise of the Over-allotment Option), after taking into account the Shares to be subscribed by Star Focus under the International Offering.*
5. *For details of the consent under paragraph 1C(1) of the Placing Guidelines and Chapter 4.15 of the Listing Guide in relation to allocations to a connected client, please refer to the section headed “Others/Additional Information – Placing to a connected client with prior consent under paragraph 1C(1) of the Placing Guidelines” in this announcement.*

## LOCK-UP UNDERTAKINGS

### Cornerstone Investors

<i>Investor</i> <sup>Note 1</sup>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertaking</i> <sup>Note 1</sup>
BPV and HTCI (in connection with Huatai Back-to-back TRS and the Huatai Client TRS)	4,775,600	1.73%	November 12, 2026
Huang River	3,117,800	1.13%	November 12, 2026
Prosper High	776,000	0.28%	November 12, 2026
LAV Star	974,200	0.35%	November 12, 2026
LAV Opportunities	974,200	0.35%	November 12, 2026
GSC Fund 1	565,000	0.20%	November 12, 2026
Vision Fund 1	993,800	0.36%	November 12, 2026
Horizon Fund 1	194,800	0.07%	November 12, 2026
Horizon Next Fund	194,800	0.07%	November 12, 2026
First Quarter Moon OFC – Phecda Fund	974,200	0.35%	November 12, 2026
WWHCP	389,600	0.14%	November 12, 2026
<b>Subtotal</b>	<b>13,930,000</b>	<b>5.03%</b>	
<i>Note:</i>			
<ol style="list-style-type: none"> <li>1. <i>In accordance with the relevant cornerstone investment agreements, the required lock-up ends on November 12, 2026, being six months following the Listing Date. The Cornerstone Investors will cease to be prohibited from disposing of or transferring H Shares subscribed for pursuant to the relevant cornerstone investment agreements after the indicated date.</i></li> </ol>			

***Other Existing Shareholders (including the Pre-IPO Investors as defined in the “History, Development and Corporate Structure” section of the Prospectus)***

<i>Name</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings <sup>Note 1</sup></i>
Sui Xiong Cai (蔡遂雄)	8,422,233	3.05%	May 12, 2027
Ye Edward Tian (田野)	8,422,233	3.05%	May 12, 2027
Bao Jun	2,767,497	1.00%	May 12, 2027
Yu Qingzhen (于慶貞)	39,722	0.01%	May 12, 2027
Decheng IMPACT Limited	23,559,685	8.53%	May 12, 2027
LAV Enterprise Hong Kong Limited (“LAV Enterprise”) <sup>Note 2</sup>	14,220,861	5.15%	May 12, 2027
LAV Innovation (Hong Kong) Co., Limited (“LAV Innovation”) <sup>Note 2</sup>	8,789,975	3.18%	May 12, 2027
LAV Integra Limited (“LAV Integra”) <sup>Note 2</sup>	6,846,397	2.48%	May 12, 2027
LAV Impetus Limited (“LAV Impetus”) <sup>Note 2</sup>	6,725,827	2.44%	May 12, 2027
Shanghai Lihan Biotechnology Partnership (Limited Partnership) (上海禮瀚生物科技合夥企業(有限合夥))	14,640,236	5.30%	May 12, 2027
Suzhou Lirui Equity Investment Center (Limited Partnership) (蘇州禮瑞股權投資中心(有限合夥))	8,368,406	3.03%	May 12, 2027
Suzhou Likang Equity Investment Centre (Limited Partnership) (蘇州禮康股權投資中心(有限合夥))	5,139,637	1.86%	May 12, 2027
Shanghai Lihao Biotech, L.P. (上海禮灝生物科技合夥企業(有限合夥))	2,290,116	0.83%	May 12, 2027
Suzhou Lirun Equity Investment Centre (LP) (蘇州禮潤股權投資中心(有限合夥))	2,125,370	0.77%	May 12, 2027
Guangxi Tencent Venture Investment Co., Ltd. (廣西騰訊創業投資有限公司) (“Tencent”) <sup>Note 2</sup>	15,593,533	5.65%	May 12, 2027
BOUNDLESS CREEK, LLC	10,875,618	3.94%	May 12, 2027
Wanquandao Biomedical Technology Partnership (Limited Partnership) (杭州萬全島生物醫藥科技合夥企業(有限合夥))	4,274,984	1.55%	May 12, 2027
Hangzhou Qianxishan Biopharmaceutical Technology Partnership (Limited Partnership) (杭州千溪山生物醫藥科技合夥企業(有限合夥))	2,986,905	1.08%	May 12, 2027
Wuhan Biolake China Summit Fund Partnership (Limited Partnership) (武漢光谷生物城華嶺基金合夥企業(有限合夥))	4,362,991	1.58%	May 12, 2027

<i>Name</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings <sup>Note 1</sup></i>
Shanghai China Summit Zhixin Investment Partnership (Limited Partnership) (上海華嶺智新投資合夥企業(有限合夥))	3,558,211	1.29%	May 12, 2027
China Summit Capital Limited Partnership	2,290,117	0.83%	May 12, 2027
Homerick Summit Capital Limited Partnership	2,290,117	0.83%	May 12, 2027
Suzhou Gaotejia Xinyin Huixin Equity Investment Partnership (Limited Partnership) (蘇州高特佳信銀匯鑫股權投資合夥企業(有限合夥))	8,615,202	3.12%	May 12, 2027
Shanghai Yunan Enterprise Management Partnership (Limited Partnership) (上海譽楠企業管理合夥企業(有限合夥))	4,580,233	1.66%	May 12, 2027
Guangzhou Yuexiu Bioindustry Venture Capital Limited Partnership (Limited Partnership) (廣州越秀生物產業創業投資基金合夥企業(有限合夥))	3,588,778	1.30%	May 12, 2027
Yangzhou Guojin Yingpai Biomedical Venture Capital Partnership (Limited Partnership) (揚州國金英派生物醫藥創業投資合夥企業(有限合夥))	7,944,585	2.88%	May 12, 2027
Shanghai Junshi Biosciences Co., Ltd. (上海君實生物醫藥科技股份有限公司)	7,907,133	2.86%	May 12, 2027
Beijing New Power Equity Investment Fund (Limited Partnership) (北京新動力股權投資基金(有限合夥))	6,030,642	2.18%	May 12, 2027
Shanghai Kangjun Business Management Consulting Partnership (Limited Partnership)(上海康鋆企業管理諮詢合夥企業(有限合夥))	6,030,649	2.18%	May 12, 2027
Hainan Yuema Zhengchun Venture Investment Center (Limited Partnership) (海南躍馬爭春創業投資中心(有限合夥))	4,307,601	1.56%	May 12, 2027
Xiamen C&D Emerging Industries Equity Investment No. 7 Partnership (Limited Partnership) (廈門建發新興產業股權投資柒號合夥企業(有限合夥))	4,013,156	1.45%	May 12, 2027
Everspring GQ Investment Fund L.P.	3,664,188	1.33%	May 12, 2027

<i>Name</i>	<i>Number of H Shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)</i>	<i>Last day subject to the lock-up undertakings <sup>Note 1</sup></i>
WuXi AppTec Investment Fund I L.P. (無錫藥明康德一期投資企業(有限合夥))	3,029,306	1.10%	May 12, 2027
Gongqingcheng Ruiji Fund III Investment Partnership (Limited Partnership) (共青城瑞吉三期投資合夥企業(有限合夥))	2,372,140	0.86%	May 12, 2027
Dingxin Capital Biotech Ventures Limited	2,290,116	0.83%	May 12, 2027
Eagle Mind Investments Limited	2,290,116	0.83%	May 12, 2027
Suzhou Industrial Park Sungen Bio-Venture Capital Investment Enterprise (Limited Partnership) (蘇州工業園區新建元生物創業投資企業(有限合夥))	2,134,448	0.77%	May 12, 2027
Hangzhou Haibang Medicine Valley Congzheng Venture Capital Investment Partnership (Limited Partnership) (杭州海邦藥谷從正創業投資合夥企業(有限合夥))	2,134,448	0.77%	May 12, 2027
Ausun (Hong Kong) Industrial Co., Limited (奧翔(香港)實業有限公司)	1,581,427	0.57%	May 12, 2027
AlphaTech Projects Limited	1,313,865	0.48%	May 12, 2027
Lakeshore LSV Limited	853,380	0.31%	May 12, 2027
Emerging Markets Healthcare Partners LLC	595,430	0.22%	May 12, 2027
WWHCP <sup>Note 2</sup>	320,616	0.12%	May 12, 2027
<b>Subtotal</b>	<b>234,188,130</b>	<b>84.80%</b>	

*Note:*

1. The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Laws. The required lock-up for existing Shareholders ends on May 12, 2027, being 12 months following the Listing Date.

2. The numbers of Shares held by LAV Enterprise, LAV Innovation, LAV Integra, LAV Impetus, Tencent, and WWHCP in the table above do not take into account the Shares to be subscribed by them and/or their respective close associates in the Global Offering. The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a consent under paragraph 1C (2) of Appendix F1 and a waiver from strict compliance with the requirements under Rule 9.09(b) (where applicable) and Rule 10.04 of the Listing Rules to permit the Company to allocate such Offer Shares in the International Offering to themselves and/or their respective close associates. For details, please refer to the sections headed "Allottees with Waivers/Consents Obtained" and "Others/Additional Information" in this announcement.

## PLACEE CONCENTRATION ANALYSIS

Placees	* Numbers of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Option is exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Overallotment Option)	Allotment as % of total Offer Shares (assuming the Overallotment Option is exercised and new H Shares are issued)	Number of H Shares held upon Listing	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Overallotment Option is exercised and new H Shares are issued)
Top 1	4,775,600	12.64%	10.84%	11.38%	9.89%	4,775,600	1.73%	1.69%
Top 5	19,576,400	51.82%	44.42%	46.64%	40.55%	35,169,933	12.74%	12.45%
Top 10	29,298,200	77.55%	66.47%	69.80%	60.69%	81,474,793	29.50%	28.84%
Top 25	42,363,400	112.13%	96.12%	100.92%	87.76%	101,486,688	36.75%	35.93%

*Note:*

\* Ranking of placees is based on the number of H Shares allotted to the placees.

## H SHAREHOLDERS CONCENTRATION ANALYSIS

H Shareholders	* Numbers of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Option is exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Overallotment Option)	Allotment as % of total Offer Shares (assuming the Overallotment Option is exercised and new H Shares are issued)	Number of H Shares held upon Listing	% of total issued H Shares capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued H Shares capital upon Listing (assuming the Overallotment Option is exercised and new H Shares are issued)	Number of Shares held upon Listing
Top 1	1,948,400	5.16%	4.42%	4.64%	4.04%	38,531,460	13.95%	13.64%	38,531,460
Top 5	5,842,200	15.46%	13.25%	13.92%	12.10%	132,279,750	47.90%	46.83%	132,279,750
Top 10	5,842,200	15.46%	13.25%	13.92%	12.10%	178,409,865	64.60%	63.16%	178,409,865
Top 25	23,231,200	61.49%	52.71%	55.34%	48.12%	246,155,878	89.13%	87.15%	246,155,878

*Note:*

\* Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.

## SHAREHOLDERS CONCENTRATION ANALYSIS

	* Numbers of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Overallotment Option)	Allotment as % of total Offer Shares (assuming the Overallotment Option is exercised and new H Shares are issued)	Number of Shares held upon Listing	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is exercised and new H Shares are issued)
All Shareholders								
Top 1	1,948,400	5.16%	4.42%	4.64%	4.04%	38,531,460	13.95%	13.64%
Top 5	5,842,200	15.46%	13.25%	13.92%	12.10%	132,279,750	47.90%	46.83%
Top 10	5,842,200	15.46%	13.25%	13.92%	12.10%	178,409,865	64.60%	63.16%
Top 25	23,231,200	61.49%	52.71%	55.34%	48.12%	246,155,878	89.13%	87.15%

*Note:*

\* *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholder upon Listing.*

## BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
<b>POOL A</b>			
200	67,375	1,010 out of 67,375 to receive 200 Shares	1.50%
400	31,423	487 out of 31,423 to receive 200 Shares	0.77%
600	7,145	114 out of 7,145 to receive 200 Shares	0.53%
800	4,135	68 out of 4,135 to receive 200 Shares	0.41%
1,000	5,633	96 out of 5,633 to receive 200 Shares	0.34%
1,200	2,889	51 out of 2,889 to receive 200 Shares	0.29%
1,400	2,481	45 out of 2,481 to receive 200 Shares	0.26%
1,600	2,331	43 out of 2,331 to receive 200 Shares	0.23%
1,800	2,223	43 out of 2,223 to receive 200 Shares	0.21%
2,000	21,604	422 out of 21,604 to receive 200 Shares	0.20%
3,000	5,244	115 out of 5,244 to receive 200 Shares	0.15%
4,000	6,287	153 out of 6,287 to receive 200 Shares	0.12%
5,000	2,883	77 out of 2,883 to receive 200 Shares	0.11%
6,000	1,867	55 out of 1,867 to receive 200 Shares	0.10%
7,000	1,308	41 out of 1,308 to receive 200 Shares	0.09%



			APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT/BALLOT	
8,000	1,141	39 out of 1,141 to receive 200 Shares	0.09%
9,000	1,085	40 out of 1,085 to receive 200 Shares	0.08%
10,000	7,202	282 out of 7,202 to receive 200 Shares	0.08%
20,000	6,048	380 out of 6,048 to receive 200 Shares	0.06%
30,000	4,890	424 out of 4,890 to receive 200 Shares	0.06%
40,000	4,190	463 out of 4,190 to receive 200 Shares	0.06%
50,000	2,441	328 out of 2,441 to receive 200 Shares	0.05%
60,000	1,914	302 out of 1,914 to receive 200 Shares	0.05%
70,000	1,434	260 out of 1,434 to receive 200 Shares	0.05%
80,000	1,524	313 out of 1,524 to receive 200 Shares	0.05%
90,000	1,259	289 out of 1,259 to receive 200 Shares	0.05%
100,000	8,062	2,041 out of 8,062 to receive 200 Shares	0.05%
200,000	5,128	2,514 out of 5,128 to receive 200 Shares	0.05%
	<u>211,146</u>	Total number of Pool A successful applicants: 10,495	
<b>POOL B</b>			
300,000	5,016	3,182 out of 5,016 to receive 200 Shares	0.04%
400,000	1,603	1,199 out of 1,603 to receive 200 Shares	0.04%
500,000	903	778 out of 903 to receive 200 Shares	0.03%
600,000	503	200 Shares	0.03%
700,000	397	200 Shares plus 33 out of 397 to receive additional 200 Shares	0.03%
800,000	250	200 Shares plus 50 out of 250 to receive additional 200 Shares	0.03%
900,000	184	200 Shares plus 57 out of 184 to receive additional 200 Shares	0.03%
1,000,000	444	200 Shares plus 191 out of 444 to receive additional 200 Shares	0.03%
1,250,000	227	200 Shares plus 162 out of 227 to receive additional 200 Shares	0.03%
1,500,000	148	400 Shares	0.03%
1,750,000	127	400 Shares plus 35 out of 127 to receive additional 200 Shares	0.03%
2,098,800	840	400 Shares plus 572 out of 840 to receive additional 200 Shares	0.03%
	<u>10,642</u>	Total number of Pool B successful applicants: 8,279	

*As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.*

## **COMPLIANCE WITH LISTING RULES AND GUIDANCE**

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the places or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

## **OTHERS/ADDITIONAL INFORMATION**

### **Allocation of H Shares to Certain Existing Shareholders and/or Their Close Associates**

#### ***As Cornerstone Investors***

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a consent under paragraph 1C (2) of Appendix F1 and a waiver from strict compliance with the requirements under Rule 9.09(b) (where applicable) and Rule 10.04 of the Listing Rules to permit H Shares in the International Offering to be placed to the Existing Shareholders and their Close Associates to participate in the Global Offering as a cornerstone investor on the following basis as set out in Paragraph 18 of Chapter 2.3 and Chapter 4.15 of the Guide, subject to the conditions as follows:

- (a) the Company will comply with the public float requirement under Rule 19A.13A of the Listing Rules and the free float requirement under Rule 19A.13C of the Listing Rules;
- (b) no preference in allocation has been, nor will be, given to WWHCP, LAV Star, LAV Opportunities, Huang River, and Prosper High or its respective close associate(s) by virtue of their relationship with the Company other than the preferential treatment of assured entitlement at the Offer Price under a cornerstone investment and the terms of the cornerstone investment agreement with WWHCP, LAV Star, LAV Opportunities, Huang River, and Prosper High or its respective close associate(s) are substantially the same as the other cornerstone investment agreements following the principles set out in Chapters 2.3 and 4.15 of the Guide;
- (c) the Shares to be subscribed by and allocated to WWHCP, LAV Star, LAV Opportunities, Huang River, and Prosper High under the Global Offering will be at the same Offer Price and on substantially the same terms, or no more favorable than, the terms of the other cornerstone investors (including being subject to a lock-up period of six months from the Listing Date) and WWHCP, LAV Star, LAV Opportunities, Huang River, and Prosper High shall pay and settle in full the consideration for the relevant Offer Shares before dealings commence on the Listing Date;
- (d) each of the Company, the Joint Sponsors and the Overall Coordinators has provided the Stock Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the Guide; and
- (e) the relevant information in respect of the allocation to WWHCP, LAV Star, LAV Opportunities, Huang River, and Prosper High as Cornerstone Investors has been disclosed in the allotment results announcement.

All allocations of Offer Shares to the Existing Shareholders and/or their close associates are in compliance with all the conditions under the waiver and consent granted by the Stock Exchange.

Please refer to the section headed “Waivers and Exemptions – Consent and Waiver in respect of Allocation of H Shares to Certain Existing Shareholders and/or Their Close Associates” in the Prospectus for further details of the waiver and consent.

## *As Placees*

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted to the Company, a consent under paragraph 1C (2) of Appendix F1 and a waiver from strict compliance with the requirements under Rule 10.04 of the Listing Rules to permit H Shares in the International Offering to be placed to the Existing Shareholders and their Close Associates to participate in the Global Offering on the following basis as set out in Paragraph 18 of Chapter 2.3 and Chapter 4.15 of the Guide, subject to the conditions as follows:

- (a) since none of the Permitted Participants, together with the involved existing Shareholder, is, and will be, a core connected person of the Company, the allocation to the Permitted Participants will not affect the Company's ability to satisfy the public float requirement under Rule 19A.13A of the Listing Rules and the free float requirement under Rule 19A.13C of the Listing Rules;
- (b) to the best knowledge and belief of the Company and based on the confirmation required to be submitted to the Stock Exchange, the Company will confirm to the Stock Exchange that no preferential treatment has been, nor will be, given to any Permitted Participant by virtue of its relationship with the Company in any allocation in the International Offering, and that such allocation will not prejudice or unfairly treat any public investors in their investment decision-making process;
- (c) the Overall Coordinators will confirm to the Stock Exchange that, to the best of their knowledge and belief, no preferential treatment has been, nor will be, given to any Permitted Participant by virtue of its relationship with the Company in any allocation in the International Offering and that such allocation will not prejudice or unfairly treat any public investors in their investment decision-making process;
- (d) each of the Company, the Joint Sponsors and the Overall Coordinators has provided the Stock Exchange with written confirmations in accordance with Chapters 2.3 and 4.15 of the Guide; and
- (e) the relevant information in respect of the allocation to the Permitted Participants has been disclosed in the allotment results announcement.

For details of the allocations of Offer Shares to the existing Shareholder and/or their close associates, please refer to the section headed "Allotment Results Details – International Offering – Allottees with Waivers/Consents Obtained" in this announcement.

## Placing to a connected client with prior consent under paragraph 1C(1) of the Placing Guidelines

Under the International Offering, certain Offer Shares were placed to a connected client of a connected distributor pursuant to the Placing Guidelines. Details of the placement to this connected client are set out below.

Connected Client	Connected Distributor	Relationship with the Connected Distributor	Whether the Connected Client will hold the beneficial interests of the Offer Shares on a non-discretionary basis or discretionary basis for independent third parties	Number of Offer Shares to be allocated	Approximate percentage of Offer Shares in the Global Offering <sup>(1)</sup>	Approximate percentage of the total issued share capital immediately following completion of the Global Offering <sup>(1)</sup>	Approximate percentage of Offer Shares in the Global Offering <sup>(2)</sup>	Approximate percentage of the total issued share capital immediately following completion of the Global Offering <sup>(2)</sup>
CICC Financial Trading Limited (“CICC FT”) <sup>(3)</sup>	CICC HK	CICC FT is a member of the same group of companies as CICC HK.	Non-discretionary	5,800	0.0138%	0.0021%	0.0120%	0.0021%
China Asset Management (Hong Kong) Limited (“China AMC”) <sup>(4)</sup>	CSB	China AMC is a member of the same group of companies as CSB.	Discretionary	4,200	0.0100%	0.0015%	0.0087%	0.0015%

**Notes:**

1. Assuming the Over-allotment Option is not exercised.
2. Assuming the Over-allotment Option is fully exercised.
3. CICC FT, which intends to participate in the International Offering as a placee, and China International Capital Corporation Limited will enter into a series of cross border delta-one OTC swap transactions (the “**OTC Swaps**”) with each other and the ultimate clients (the “**CICC FT Ultimate Clients**”), pursuant to which CICC FT will hold the Offer Shares on a non-discretionary basis to hedge the OTC Swaps while the economic risks and returns of the underlying Offer Shares are passed to the CICC FT Ultimate Clients subject to customary fees and commissions. The OTC Swaps will be fully funded by the CICC FT Ultimate Clients. During the terms of the OTC Swaps, all economic returns of the Offer Shares subscribed by CICC FT will be passed to the CICC FT Ultimate Clients and all economic loss shall be borne by the CICC FT Ultimate Clients through the OTC Swaps, and CICC FT will not take part in any economic return or bear any economic loss in relation to the Offer Shares. The OTC Swaps are linked to the Offer Shares and the CICC FT Ultimate Clients may request CICC FT to redeem it at their own discretion, upon which CICC FT shall dispose of the Offer Shares and settle OTC Swaps in cash in accordance with the terms and conditions of the OTC Swap. Despite that CICC FT will hold the legal title of the Offer Shares by itself, it will not exercise the voting rights attaching to the relevant Offer Shares during the terms of the OTC Swaps according to its internal policy. Each of the CICC FT Ultimate Clients for purpose of this placee subscription is an independent third party of CICC FT, CICCHKS and the companies which are members of the same group of companies as each of the Underwriters.

The details of the CICC FT Ultimate Client are as follows:

<b>Name of CICC FT Ultimate Clients<sup>(1)</sup></b>	<b>Fund manager(s)<sup>(2)</sup></b>	<b>Ultimate Beneficial Owner (“UBO”) of Fund Manager</b>	<b>Limited Partner/Shareholding holding 30% or more in the CICC FT Ultimate Client</b>
Yuanzheng Tianli No.3 Private Securities Investment Fund (遠征添利3號私募證券投資基金)	Beijing Hengde Era Fund Management Co. Ltd. (北京恒德時代私募基金管理有限公司)	N/A	Not applicable as there is no limited partner holding 30% or more
Yuanzheng Jinxin No.4 Private Securities Investment Fund(遠征金信 4 號私募證券投資基金)	Beijing Hengde Era Fund Management Co. Ltd. (北京恒德時代私募基金管理有限公司)	N/A	Not applicable as there is no limited partner holding 30% or more
Hengde Jinze E49 Private Securities Investment Fund (恒德金澤 E49 號私募證券投資基金)	Beijing Hengde Era Fund Management Co. Ltd. (北京恒德時代私募基金管理有限公司)	N/A	Tsinghua University Education Foundation <sup>3</sup>
Longrising Qiangshu Private Securities Investment Fund (源樂晟強樹私募證券投資基金)	Tibet Longrising Capital Management Co., Ltd.(西藏源樂晟資產管理有限公司)	ZENG Xiaojie	ZENG Xiaojie (shareholding interests: 98.36%)
Longrising Qiangye Private Securities Investment Fund (源樂晟強業私募證券投資基金)	Tibet Longrising Capital Management Co., Ltd.(西藏源樂晟資產管理有限公司)	ZENG Xiaojie	ZENG Xiaojie (shareholding interests: 42.31%)

To the best knowledge, information and belief of CICC FT after due enquiry, (i) the CICC FT Ultimate Clients are independent third parties of CICC FT, CICC HK and the companies which are members of the same group of CICC HK; (ii) the ultimate beneficial owners holding 30% or more interest of the CICC FT Ultimate Clients as set out below, each of which is an independent third party of the CICC FT, CICC HK and the companies which are members of the same group of CICC HK; and (iii) the CICC FT Ultimate Clients are independent third parties of the Company, the subsidiaries, and substantial shareholders of the Company.

(1) English Names are for identification purpose only.

(2) English Names are for identification purpose only.

(3) As Tsinghua University Education Foundation (清華大學教育基金會) is a non-profit organization (NGO), it does not have any equity holders or ultimate beneficial owners. Its primary funding comes from social donations.



4. CSB is a sub-distributor of the Global Offering. China AMC will hold the Offer Shares in its capacity as the discretionary fund manager managing assets on behalf of its underlying clients, each of which is an independent third party (“**China AMC Ultimate Clients**”). CSB is a wholly owned subsidiary of CITIC Securities Company Limited (a company listed on the Stock Exchange, stock code: 6030 “**CITIC Securities**”), China AMC is controlled as to 62.2% by CITIC Securities. Therefore, China AMC is a member of the same group of companies as CSB Connected Distributors.

The details of the China AMC Ultimate Clients are as follow:

<b>Name of China AMC Ultimate Clients</b>	<b>Fund manager(s)</b>	<b>UBO of Fund Manager</b>	<b>Limited Partner/Shareholding holding 30% or more in the China AMC Ultimate Clients</b>
CHINAAMC SELECT GREATER CHINA TECHNOLOGY FUND	China Asset Management (Hong Kong) Limited	CITIC Securities	Futu Securities International (Hong Kong) Limited (wholly-owned by Futu Holdings Limited, FUTU.O/NASDAQ)-client account
CHINAAMC FUND	China Asset Management (Hong Kong) Limited	CITIC Securities	Not applicable as there is no limited partner holding 30% or more
CHINAAMC CHINA FOCUS FUND	China Asset Management (Hong Kong) Limited	CITIC Securities	Manulife (International) Limited (wholly-owned by Manulife Financial Corp, MFC.TO/0045.HK)
CHINAAMC CHINA GROWTH FUND	China Asset Management (Hong Kong) Limited	CITIC Securities	Yuanta Securities (HK) Company LTD (wholly-owned by Yuanta Financial Holding, 2885.TW)-client account
HKCINDAM	China Asset Management (Hong Kong) Limited	CITIC Securities	China Cinda (HK) Asset Management CO., LTD (wholly-owned by China Cinda Asset Management Co., LTD, 1359.HK)

To the best knowledge of China AMC and after making all reasonable enquiries, China AMC Ultimate Client, together with its ultimate beneficial owners, is an independent third party of the Company, its subsidiaries, its substantial shareholders, China AMC, CSB, CITIC Securities and the companies which are members of the same group of companies as each of the Overall Coordinators and Underwriters, respectively.

5. Each of the Connected Clients is not a collective investment scheme which is not authorized by the SFC, nor is expected to hold the Offer Shares on behalf of such scheme.

The Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a consent under paragraph 1C(1) of the Placing Guidelines to permit the Company to allocate such Offer Shares in the International Offering to the connected client listed above. The allocation of Offer Shares to such connected client is in compliance with all the conditions under the consent granted by the Stock Exchange.

## DISCLAIMERS

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited (“HKSCC”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “U.S. Securities Act”) or any state securities law of the United States. The securities may not be offered, sold, pledged or transferred within the United States, except in transactions exempt from, or not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offer of the Offer Shares in the United States.*

*The Offer Shares are being offered and sold solely (1) to qualified institutional buyers as defined in Rule 144A under the U.S. Securities Act pursuant to an exemption from registration under the U.S. Securities Act; and (2) outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and applicable laws of each jurisdiction where those offers and sales occur.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus dated May 5, 2026 issued by IMPACT Therapeutics, Inc (南京英派藥業股份有限公司) for detailed information about the Global Offering described below before deciding whether or not to invest in the H Shares thereby being offered.*

*\* Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on May 13, 2026).*

## **PUBLIC FLOAT AND FREE FLOAT**

Immediately following the completion of the Global Offering (before any exercise of the Over-Allotment Option), the expected market capitalization of the Company's H Shares would be approximately HK\$5,551 million, calculated based on the final Offer Price of HK\$20.10. Under Rule 19A.13A(1), the minimum public float of the Company shall be 25% based on the final Offer Price of HK\$20.10. The total number of listed H Shares held by the public (being 157,586,496 H Shares) represents approximately 57.06% of the total issued Shares of the Company upon Listing, taking into account the actual number of Offer Shares allocated to cornerstone investors that are core connected Shareholders. For details of the Shares held by certain of our Shareholders which shall not be counted towards the public float, see "History, Development and Corporate Structure – Capitalization" in the Prospectus for details. Therefore, the Company will be able to meet the minimum public float requirement under Rule 19A.13A.

Immediately following the completion of the Global Offering (before any exercise of the Over-allotment Option) and based on the final Offer Price of HK\$20.10 per Offer Share, the expected market value of the H Shares held by the public and not subject to disposal restrictions will be approximately HK\$563.7 million, representing approximately 10.16% of the total issued Shares of the Company upon Listing. As such, the Company will be able to satisfy the free float requirement under Rule 19A.13C(1)(a) of the Listing Rules.

The Directors confirm that immediately following the completion of the Global Offering (before any exercise of the Over-allotment Option), (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public shareholders of the Company do not hold more than 50% of the H Shares in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

## **COMMENCEMENT OF DEALINGS**

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday, May 13, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed "Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination" in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Wednesday, May 13, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Wednesday, May 13, 2026 (Hong Kong time). The H Shares will be traded in board lots of 200 H Shares each, and the stock code of the H Shares will be 7630.

By order of the Board  
**IMPACT Therapeutics, Inc**  
**Dr. Sui Xiong CAI**  
*Executive Director and Chief Executive Officer*

Hong Kong, May 12, 2026

*As at the date of this announcement, the Board comprises (i) Dr. Sui Xiong CAI, Dr. Ye Edward TIAN and Ms. Ning MA as executive directors; (ii) Dr. Cong XU, Dr. Qiang XU and Mr. Tao LIU as non-executive directors; and (iii) Dr. Edward Ming GUO, Mr. Chi Hung SIU and Dr. Liming SHAO as proposed independent non-executive directors.*